Abstract

The aim of the prospective study was to investigate the clinical efficacy of Tamistol and Bifiten in the complex treatment of salpingoophoritis.Patients and methods. The study involved 152 patients of reproductive age with salpingoophoritis. All women were divided into 3 groups: I – 48 patients received traditional therapy; II – 54 patients who received complex anti-inflammatory treatment with vaginal application of a combined drug containing neomycin sulfate 35,000 IU, polymyxin B sulfate 35,000 IU and nystatin 100,000 IU; III – 50 women, each of whom in addition to traditional therapy received Tamistol and the synbiotic Bifiten. The comparative assessment of the effectiveness of treatment was conducted on the basis of regression of women’s complaints and the results of bacteriological research in dynamics.Results. The local application of suppositories Tamistol or combined drug with neomycin sulfate, polymyxin B sulfate and nystatin had a pronounced clinical effect in the treatment of salpingooophoritis. However, the use of suppositories of Tamistol and Bifiten capsules were more effective than the use of combined drug to reduce the incidence of dysbiosis (RR 2.01, 95% CI 1.14–3.53, p = 0.02 and RR 4.63, 95% CI 1.43–15.04, p = 0.01), for a higher number of lactobacilli (RR 1.99, 95% CI 1.17–3.40, p = 0.011 and RR 5.45 95% CI 1,71–17,41, p = 0,004) on the 14th and 30th day of the study.Conclusion. Use of suppositories Tamistol and capsules Bifiten was clinically highly effective in the complex therapy of salpingoophoritis. The combination of suppositories Tamistol and Bifiten capsules per os requires further investigation.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.